These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30056571)

  • 1. Reduction toxicity of Amphotericin B through loading into a novel nanoformulation of anionic linear globular dendrimer for improve treatment of leishmania major.
    Mehrizi TZ; Ardestani MS; Khamesipour A; Hoseini MHM; Mosaffa N; Anissian A; Ramezani A
    J Mater Sci Mater Med; 2018 Jul; 29(8):125. PubMed ID: 30056571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis between four model nanoformulations of amphotericin B-chitosan, amphotericin B-dendrimer, betulinic acid-chitosan and betulinic acid-dendrimer for treatment of
    Zadeh Mehrizi T; Khamesipour A; Shafiee Ardestani M; Ebrahimi Shahmabadi H; Haji Molla Hoseini M; Mosaffa N; Ramezani A
    Int J Nanomedicine; 2019; 14():7593-7607. PubMed ID: 31802863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis.
    Abu Ammar A; Nasereddin A; Ereqat S; Dan-Goor M; Jaffe CL; Zussman E; Abdeen Z
    Drug Deliv Transl Res; 2019 Feb; 9(1):76-84. PubMed ID: 30484256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis.
    Daftarian PM; Stone GW; Kovalski L; Kumar M; Vosoughi A; Urbieta M; Blackwelder P; Dikici E; Serafini P; Duffort S; Boodoo R; Rodríguez-Cortés A; Lemmon V; Deo S; Alberola J; Perez VL; Daunert S; Ager AL
    J Infect Dis; 2013 Dec; 208(11):1914-22. PubMed ID: 23901083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poloxamer 407 (Pluronic(®) F127)-based polymeric micelles for amphotericin B: In vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasis.
    Mendonça DV; Lage LM; Lage DP; Chávez-Fumagalli MA; Ludolf F; Roatt BM; Menezes-Souza D; Faraco AA; Castilho RO; Tavares CA; Barichello JM; Duarte MC; Coelho EA
    Exp Parasitol; 2016 Oct; 169():34-42. PubMed ID: 27427166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bovine serum albumin nanoparticles containing amphotericin B were effective in treating murine cutaneous leishmaniasis and reduced the drug toxicity.
    Casa DM; Scariot DB; Khalil NM; Nakamura CV; Mainardes RM
    Exp Parasitol; 2018 Sep; 192():12-18. PubMed ID: 30026113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of a Tiered
    Caridha D; Parriot S; Hudson TH; Lang T; Ngundam F; Leed S; Sena J; Harris M; O'Neil M; Sciotti R; Read L; Lecoeur H; Hickman M; Grogl M
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neolignan Licarin A presents effect against Leishmania (Leishmania) major associated with immunomodulation in vitro.
    Néris PL; Caldas JP; Rodrigues YK; Amorim FM; Leite JA; Rodrigues-Mascarenhas S; Barbosa-Filho JM; Rodrigues LC; Oliveira MR
    Exp Parasitol; 2013 Oct; 135(2):307-13. PubMed ID: 23891943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leishmanicidal Activity of Isoselenocyanate Derivatives.
    Fernández-Rubio C; Larrea E; Peña Guerrero J; Sesma Herrero E; Gamboa I; Berrio C; Plano D; Amin S; Sharma AK; Nguewa PA
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30478164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel nano-sized chitosan amphotericin B formulation with considerable improvement against Leishmania major.
    Mehrizi TZ; Ardestani MS; Molla Hoseini MH; Khamesipour A; Mosaffa N; Ramezani A
    Nanomedicine (Lond); 2018 Dec; 13(24):3129-3147. PubMed ID: 30463469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the in vivo leishmanicidal activity of amphotericin B emulgel: An alternative for the treatment of skin leishmaniasis.
    Pinheiro IM; Carvalho IP; de Carvalho CE; Brito LM; da Silva AB; Conde Júnior AM; de Carvalho FA; Carvalho AL
    Exp Parasitol; 2016 May; 164():49-55. PubMed ID: 26902606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis.
    Riezk A; Van Bocxlaer K; Yardley V; Murdan S; Croft SL
    Molecules; 2020 Sep; 25(17):. PubMed ID: 32887341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An amphotericin B-based drug for treating experimental Leishmania major infection.
    Corware KD; Rogers M; Teo I; Müller I; Shaunak S
    Trans R Soc Trop Med Hyg; 2010 Nov; 104(11):749-50. PubMed ID: 20850850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical treatment with nanoliposomal Amphotericin B reduces early lesion growth but fails to induce cure in an experimental model of cutaneous leishmaniasis caused by Leishmania mexicana.
    Varikuti S; Oghumu S; Saljoughian N; Pioso MS; Sedmak BE; Khamesipour A; Satoskar AR
    Acta Trop; 2017 Sep; 173():102-108. PubMed ID: 28602835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amphotericin B inhibits entry of Leishmania donovani into primary macrophages.
    Paila YD; Saha B; Chattopadhyay A
    Biochem Biophys Res Commun; 2010 Aug; 399(3):429-33. PubMed ID: 20678487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanonization increases the antileishmanial efficacy of amphotericin B: an ex vivo approach.
    Manandhar KD; Yadav TP; Prajapati VK; Basukala O; Aganja RP; Dude A; Shrivastav ON; Sundar S
    Adv Exp Med Biol; 2014; 808():77-91. PubMed ID: 24595612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of leishmanicidal activity and cytotoxicity of Ricinus communis and Azadirachta indica extracts from western Kenya: in vitro and in vivo assays.
    Jumba BN; Anjili CO; Makwali J; Ingonga J; Nyamao R; Marango S; Choge JK; Khayeka-Wandabwa C
    BMC Res Notes; 2015 Nov; 8():650. PubMed ID: 26541197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid nanoparticles for amphotericin delivery in the treatment of American tegumentary leishmaniasis.
    de Souza RM; Maranhão RC; Tavares ER; Filippin-Monteiro FB; Nicodemo AC; Morikawa AT; Kanashiro EHY; Amato VS
    Drug Deliv Transl Res; 2020 Apr; 10(2):403-412. PubMed ID: 31701487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nano-based antileishmanial agents: a toxicological study on nanoparticles for future treatment of cutaneous leishmaniasis.
    Jebali A; Kazemi B
    Toxicol In Vitro; 2013 Sep; 27(6):1896-904. PubMed ID: 23806227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential application of nanochitosan film as a therapeutic agent against cutaneous leishmaniasis caused by L. major.
    Bahrami S; Esmaeilzadeh S; Zarei M; Ahmadi F
    Parasitol Res; 2015 Dec; 114(12):4617-24. PubMed ID: 26346452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.